Chiome Bioscience Inc. (4583) AI Stock Analysis

• Market Cap: ¥7.56B
• Dividend Yield: N/A
• Average Volume (3M): 521.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 25.28%
• EPS Growth: 39.15%
• Country: JP
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 72,651,300
• 10 Day Avg. Volume: 796,530
• 30 Day Avg. Volume: 521,303
• PEG Ratio: 0.42
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 12.25
• P/FCF Ratio: -7.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ¥101.00 ▼(-4.72% Downside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is constrained primarily by weak financial performance—persistent large losses and ongoing cash burn—despite modest leverage. Technicals are neutral-to-slightly constructive near term but remain below longer-term averages, and valuation is limited by negative earnings (negative P/E) with no dividend yield data.

Positive Factors

Gross Margin Durability

Sustained gross margins near 55–60% indicate the company’s core R&D and discovery activities retain value capture potential. In biotech, strong product-level margins support long-term partner economics and make licensing or royalty monetization more viable as programs advance.

Negative Factors

Persistent Cash Burn

Consistent negative operating and free cash flow show the company’s losses translate into real cash outflows, increasing dependence on external financing or partner deals. Over months, persistent burn elevates dilution and execution risk if new funding or milestone receipts are delayed.

Chiome Bioscience Inc. Business Overview & Revenue Model

Company Description

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a mono...

Read more

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a mono...

How the Company Makes Money

Chiome Bioscience primarily generates revenue through biopharmaceutical R&D monetization rather than high-volume product sales. Key revenue streams typically include (1) licensing out its drug candidates and/or proprietary technologies to pharmace...

Read more

Chiome Bioscience primarily generates revenue through biopharmaceutical R&D monetization rather than high-volume product sales. Key revenue streams typically include (1) licensing out its drug candidates and/or proprietary technologies to pharmace...

Chiome Bioscience Inc. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	768.88M	593.29M	780.81M	682.46M	630.82M	712.93M
Gross Profit	436.96M	355.58M	432.02M	397.72M	347.78M	420.59M
EBITDA	-985.98M	-976.03M	-1.03B	-1.20B	-1.26B	-1.33B
Net Income	-997.11M	-982.78M	-1.02B	-1.22B	-1.24B	-1.48B
Balance Sheet
Total Assets	1.96B	1.73B	2.47B	1.75B	2.22B	2.34B
Cash, Cash Equivalents and Short-Term Investments	1.47B	1.21B	2.06B	1.33B	1.73B	1.79B
Total Debt	260.50M	261.70M	281.50M	291.00M	184.00M	183.00M
Total Liabilities	443.39M	605.44M	548.55M	593.73M	424.72M	446.39M
Stockholders Equity	1.52B	1.12B	1.92B	1.16B	1.79B	1.89B
Cash Flow
Free Cash Flow	0.00	-976.07M	-1.00B	0.00	-1.19B	0.00
Operating Cash Flow	0.00	-935.99M	-1.00B	-1.07B	-1.19B	-1.13B
Investing Cash Flow	0.00	-55.46M	0.00	173.00K	0.00	-35.38M
Financing Cash Flow	0.00	133.20M	1.74B	667.30M	1.13B	271.35M

Chiome Bioscience Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 106.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Neutral. The current price of 106 is above the 20-day moving average (MA) of 105.45, below the 50-day MA of 109.48, and below the 200-day MA of 126.08, indicating a bearish trend. The MACD of -1.80 indicates Negative momentum. The RSI at 45.70 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4583.

Chiome Bioscience Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥14.02B	41.40	―	―	12.91%	37.96%
4588	55 Neutral	¥75.68B	-20.18	―	―	-9.04%	13.09%
4579	54 Neutral	¥20.74B	87.60	―	―	9.87%	-24.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4565	48 Neutral	¥91.85B	-5.96	-19.31%	―	-1.96%	-64.18%
4583	47 Neutral	¥7.56B	-7.39	―	―	25.28%	39.15%
4587	46 Neutral	¥167.48B	-57.13	-10.16%	―	-62.47%	-134.06%

Chiome Bioscience Inc. Corporate Events